This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease (PIT-ROAD)

This study has been terminated.
Kowa Company, Ltd.
Information provided by (Responsible Party):
Hiroaki Kazui, Osaka University Identifier:
First received: October 22, 2007
Last updated: May 14, 2012
Last verified: May 2012
Some studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate Alzheimer's disease and hypercholesterolemia.

Condition Intervention
Alzheimer Disease Hypercholesterolemia Drug: Pitavastatin Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Hiroaki Kazui, Osaka University:

Primary Outcome Measures:
  • Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog) [ Time Frame: baseline and 12 months ]
    Alzheimer's Disease Assessment Scale-cognitive component-Japanese version is a cognitive test for Alzheimer's disease. This test includes some aspects that assess memory ,orientation, language, praxis, and so on. The possible range of this test is 0-70 points.Higher total points indicate more impairment.

Secondary Outcome Measures:
  • MMSE, Neuropsychiatric Inventory, GDS-15, Zarit Burden Scale, Physical Self-Maintenance Scale, IADL, Everyday Memory Checklist, TC, HDL-C, Non HDL-C*, Apo A1, Apo B, Apo E *: Non HDL-C = (TC) - (HDL-C) [ Time Frame: baseline and 12 months ]
    Mini-Mental State Examination(MMSE),Geriatric Depression Scale-15(GDS-15),Instrumental Activities of Daily Living Scale(IADL),Total Cholesterol(TC)

Enrollment: 38
Study Start Date: November 2007
Study Completion Date: March 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Pitavastatin
2 mg by orally/day Duration: 12 months
Active Comparator: 2 Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
duration: 12 months

Detailed Description:

The PIT-ROAD study will include 50 patients who have taken donepezil more than 3 months stably. This study will see how the use of a particular statin medication, pitavastatin, affects ADAS-Jcog score etc. and cholesterol.

Participants will be given a full information of the study and written informed consent should be obtained before entering the study. Participants will take part in 5 visits over the course of 12 months. If participants have taken cholesterol lowering drug, they will have wash-out period at least 4weeks. Participants will undergo 8 tests (ADAS-Jcog etc., baseline and month 12 visits), complete a medical history questionnaire (baseline), complete medication side effect review through questionnaire and/or blood sample (all visits). Participants will be randomly assigned to receive either pitavastatin or other cholesterol lowering medication for 12 months.


Ages Eligible for Study:   20 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Alzheimer's Disease patients (15 ≤ MMSE total score ≤ 23, CDR "1" or "2")
  • Patients with hypercholesterolemia
  • Patients who have taken donepezil more than 3 months stably
  • Both patients and care-givers must be more than 20 years old

Exclusion Criteria:

  • Women with pregnancy or breast-feeding
  • Malignant tumor
  • Cerebrovascular disorder or myocardial infarction prior to 12 weeks
  • Heart failure [New York Heart Association (NYHA) class III or IV]
  • Hepatic or renal dysfunction
  • Severe hypertension
  • Hypothyroidism, hereditary muscular disease, history of drug-induced myopathy
  • Current involvement in another investigational drug study
  • Alcoholism, drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00548145

Osaka University Hospital
Suita, Osaka, Japan, 565-0871
Sponsors and Collaborators
Osaka University
Kowa Company, Ltd.
Principal Investigator: Hiroaki Kazui, Ph.D. Osaka University Hospital
  More Information

Additional Information:
Responsible Party: Hiroaki Kazui, M.D.Ph.D, Osaka University Identifier: NCT00548145     History of Changes
Other Study ID Numbers: OSK-07098
Study First Received: October 22, 2007
Results First Received: December 28, 2011
Last Updated: May 14, 2012

Keywords provided by Hiroaki Kazui, Osaka University:
Alzheimer's Disease
Alzheimer Disease (MMSE 15-23 and CDR1 or 2)

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on August 22, 2017